Combination Imaging Ups Differentiation of Breast Tumors

Use of new technique, which includes four approaches, could reduce unnecessary breast biopsies

Combination Imaging Ups Differentiation of Breast Tumors

MONDAY, June 30, 2014 (HealthDay News) -- Use of multiparametric 18fluorodeoxyglucose positron emission tomography magnetic resonance imaging (MP 18FDG PET-MRI) using dynamic contrast-enhanced MRI (DCE-MRI), diffusion-weighted imaging, three-dimensional proton MR spectroscopic imaging, and 18FDG-PET can improve differentiation of benign and malignant breast tumors, according to a study published online June 24 in Clinical Cancer Research.

Katja Pinker, M.D., from the Medical University of Vienna, and colleagues examined whether MP 18FDG PET-MRI improves differentiation of benign and malignant breast tumors using data from 76 female patients with an imaging abnormality. Participants underwent fused PET-MRI of the breast. The likelihood of malignancy was compared for all single parameters, for MP MRI with two/three parameters, and for MP 18FDG PET-MRI, with histopathology as the standard of reference.

The researchers found that the area under the curve (AUC) was significantly higher with MP 18FDG PET-MRI than with DCE-MRI (0.935 versus 0.86; P = 0.044) and compared with the combination of DCE-MRI and a second parameter (AUC, 0.761 to 0.826; P = 0.013 to 0.020). Further slight improvements were seen for MP 18FDG PET-MRI compared with MP MRI with three parameters (AUC, 0.925; P = 0.317). Compared with use of MP imaging with one or two parameters, MP 18FDG PET-MRI would be associated with a reduction in unnecessary breast biopsies (P = 0.002 to 0.011).

"This feasibility study shows that MP 18FDG PET-MRI enables an improved differentiation of benign and malignant breast tumors when several MRI and PET parameters are combined," the authors write. "MP 18FDG PET-MRI may lead to a reduction in unnecessary breast biopsies."

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing